K N Mmasa1, K Powis1,2,3, S Sun4, J Makhema1, M Mmalane1, S Kgole1, G Masasa1, S Moyo1,3, M Gerschenson5, T Mohammed1, J Legbedze4, E J Abrams6, I J Kurland7, M E Geffner8, J Jao1,4,9. 1. Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. 2. Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, MA, USA. 3. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, MA, USA. 4. Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. 5. Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA. 6. ICAP at Columbia, Mailman School of Public Health and Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA. 7. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. 8. The Saban Research Institute of Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA, USA. 9. Department of Pediatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
BACKGROUND: There are few data on the prevalence of gestational diabetes (GDM) in pregnant women living with HIV (WLHIV) in sub-Saharan Africa, particularly those using integrase strand transfer inhibitors such as dolutegravir (DTG). METHODS: We prospectively enrolled pregnant WLHIV and pregnant women without HIV ≥18 years old in Gaborone, Botswana, excluding those with pre-existing diabetes. We screened for GDM using a 75 g oral glucose tolerance test (OGTT) performed at 24-28 weeks' gestation or at the earliest prenatal visit for those presenting after 28 weeks. Logistic regression models were fitted to assess the association between maternal HIV infection and GDM. Subgroup analyses were performed among WLHIV to assess the association between maternal antiretroviral therapy (ART) in pregnancy [DTG vs. efavirenz (EFV) with tenofovir/emtricitabine] and GDM. RESULTS: Of 486 pregnant women, 66.5% were WLHIV, and they were older than women without HIV (median age 30 vs. 25 years, P < 0.01). Among WLHIV, 97.8% had an HIV-1 RNA level < 400 copies/mL at enrolment. Overall, 8.4% had GDM with similar rates between WLHIV and those without HIV (9.0% vs. 7.4%). The WLHIV receiving DTG-based ART had a 60% lower risk for GDM compared with those on EFV-based ART (adjusted odds ratio = 0.40, 95% CI: 0.18-0.92) after adjusting for confounders. CONCLUSIONS: Pregnant WLHIV on ART in Botswana were not at increased risk of GDM compared with women without HIV. Among WLHIV, the risk of GDM was lower with DTG- than with EFV-based ART. Further studies with larger cohorts are warranted to confirm these findings.
BACKGROUND: There are few data on the prevalence of gestational diabetes (GDM) in pregnant women living with HIV (WLHIV) in sub-Saharan Africa, particularly those using integrase strand transfer inhibitors such as dolutegravir (DTG). METHODS: We prospectively enrolled pregnant WLHIV and pregnant women without HIV ≥18 years old in Gaborone, Botswana, excluding those with pre-existing diabetes. We screened for GDM using a 75 g oral glucose tolerance test (OGTT) performed at 24-28 weeks' gestation or at the earliest prenatal visit for those presenting after 28 weeks. Logistic regression models were fitted to assess the association between maternal HIV infection and GDM. Subgroup analyses were performed among WLHIV to assess the association between maternal antiretroviral therapy (ART) in pregnancy [DTG vs. efavirenz (EFV) with tenofovir/emtricitabine] and GDM. RESULTS: Of 486 pregnant women, 66.5% were WLHIV, and they were older than women without HIV (median age 30 vs. 25 years, P < 0.01). Among WLHIV, 97.8% had an HIV-1 RNA level < 400 copies/mL at enrolment. Overall, 8.4% had GDM with similar rates between WLHIV and those without HIV (9.0% vs. 7.4%). The WLHIV receiving DTG-based ART had a 60% lower risk for GDM compared with those on EFV-based ART (adjusted odds ratio = 0.40, 95% CI: 0.18-0.92) after adjusting for confounders. CONCLUSIONS: Pregnant WLHIV on ART in Botswana were not at increased risk of GDM compared with women without HIV. Among WLHIV, the risk of GDM was lower with DTG- than with EFV-based ART. Further studies with larger cohorts are warranted to confirm these findings.
Authors: Larske M Soepnel; Shane A Norris; Verena J M M Schrier; Joyce L Browne; Marcus J Rijken; Glenda Gray; Kerstin Klipstein-Grobusch Journal: AIDS Date: 2017-01-02 Impact factor: 4.177
Authors: Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues Journal: Hepatology Date: 2010-07 Impact factor: 17.425
Authors: Denise M Scholtens; Alan Kuang; Lynn P Lowe; Jill Hamilton; Jean M Lawrence; Yael Lebenthal; Wendy J Brickman; Peter Clayton; Ronald C Ma; David McCance; Wing Hung Tam; Patrick M Catalano; Barbara Linder; Alan R Dyer; William L Lowe; Boyd E Metzger Journal: Diabetes Care Date: 2019-01-07 Impact factor: 19.112
Authors: Sumanth Karamchand; Rory Leisegang; Michael Schomaker; Gary Maartens; Lourens Walters; Michael Hislop; Joel A Dave; Naomi S Levitt; Karen Cohen Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889